跳到正文
原文
NEJM· Luke J. LaffinCleveland Clinic Coordinating Center for Clinical Research, ClevelandStephen J. NichollsVictorian Heart Institute, Melbourne, VIC, AustraliaRussell S. ScottNew Zealand Clinical Research, Christchurch, New ZealandPeter M. CliftonRoyal Adelaide Hospital, Adelaide, SA, AustraliaRenate KoopsAotearoa Clinical Trials, Auckland, New ZealandAshish SarrajuCleveland Clinic Coordinating Center for Clinical Research, ClevelandShweta SinghCRISPR Therapeutics, BostonQiuqing WangKathy WolskiCleveland Clinic Coordinating Center for Clinical Research, ClevelandHuansheng XuJen NielsenNaimish PatelJason M. DuranCRISPR Therapeutics, BostonSteven E. NissenCleveland Clinic Coordinating Center for Clinical Research, Cleveland·· 2026-08-28精选AI 评分62

CTX310 靶向 ANGPTL3 的 CRISPR-Cas9 基因编辑持久性研究

Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310

AI 导读

NEJM 刊发研究,评估 CRISPR-Cas9 基因编辑疗法 CTX310 靶向 ANGPTL3 的持久性,作者来自 Cleveland Clinic 与 CRISPR Therapeutics 等机构。该文发表于 2026 年 10 月 1 日第 395 卷第 13 期,页码 1343-1345,目前仅有摘要信息。

来源:NEJM · nejm.org